WallStSmart

American Well Corp (AMWL)vsEli Lilly and Company (LLY)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 36356% more annual revenue ($79.67B vs $218.53M). LLY leads profitability with a 33.5% profit margin vs -35.7%. LLY earns a higher WallStSmart Score of 76/100 (B+).

AMWL

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 6.5
Piotroski: 5/9Altman Z: -6.51

LLY

Strong Buy

76

out of 100

Grade: B+

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMWLUndervalued (+53.5%)

Margin of Safety

+53.5%

Fair Value

$9.30

Current Price

$12.64

$3.34 discount

UndervaluedFair: $9.30Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMWL2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.03T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
78.8%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
33.5%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
54.2%10/10

Strong operational efficiency at 54.2%

Revenue GrowthGrowth
47.7%10/10

Revenue surging 47.7% year-over-year

EPS GrowthGrowth
26.2%8/10

Earnings expanding 26.2% YoY

Areas to Watch

AMWL4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$208.70M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-38.7%2/10

ROE of -38.7% — below average capital efficiency

Revenue GrowthGrowth
-26.6%2/10

Revenue declined 26.6%

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
38.4x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.623/10

Elevated debt levels

Price/BookValuation
31.3x2/10

Trading at 31.3x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : AMWL

The strongest argument for AMWL centers on Price/Book, Debt/Equity.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.

Bear Case : AMWL

The primary concerns for AMWL are EPS Growth, Market Cap, Return on Equity.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.

Key Dynamics to Monitor

AMWL profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.

AMWL carries more volatility with a beta of 1.68 — expect wider price swings.

LLY is growing revenue faster at 47.7% — sustainability is the question.

LLY generates stronger free cash flow (7.8B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (76/100 vs 31/100), backed by strong 33.5% margins and 47.7% revenue growth. AMWL offers better value entry with a 53.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American Well Corp

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

American Well Corporation is a telehealth business enabling digital healthcare delivery. The company is headquartered in Boston, Massachusetts.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?